nodes	percent_of_prediction	percent_of_DWPC	metapath
Amoxapine—HTR7—vein—ovarian cancer	0.0225	0.113	CbGeAlD
Amoxapine—HTR2A—vein—ovarian cancer	0.014	0.0705	CbGeAlD
Amoxapine—HRH4—bone marrow—ovarian cancer	0.0114	0.0574	CbGeAlD
Amoxapine—DRD4—testis—ovarian cancer	0.00662	0.0333	CbGeAlD
Amoxapine—HTR2B—myometrium—ovarian cancer	0.00517	0.026	CbGeAlD
Amoxapine—ORM1—endometrium—ovarian cancer	0.00431	0.0217	CbGeAlD
Amoxapine—HTR2B—uterine cervix—ovarian cancer	0.00402	0.0202	CbGeAlD
Amoxapine—HTR2B—decidua—ovarian cancer	0.00383	0.0193	CbGeAlD
Amoxapine—HTR2B—endometrium—ovarian cancer	0.00364	0.0183	CbGeAlD
Amoxapine—ORM1—female reproductive system—ovarian cancer	0.00357	0.0179	CbGeAlD
Amoxapine—HTR7—epithelium—ovarian cancer	0.00348	0.0175	CbGeAlD
Amoxapine—SLC6A2—decidua—ovarian cancer	0.00341	0.0171	CbGeAlD
Amoxapine—ORM1—bone marrow—ovarian cancer	0.00337	0.0169	CbGeAlD
Amoxapine—HTR2B—uterus—ovarian cancer	0.00335	0.0169	CbGeAlD
Amoxapine—ADRA1A—epithelium—ovarian cancer	0.00335	0.0169	CbGeAlD
Amoxapine—HTR1B—female reproductive system—ovarian cancer	0.00335	0.0168	CbGeAlD
Amoxapine—HRH1—myometrium—ovarian cancer	0.00331	0.0166	CbGeAlD
Amoxapine—ADRA2A—myometrium—ovarian cancer	0.00325	0.0163	CbGeAlD
Amoxapine—HTR2C—female reproductive system—ovarian cancer	0.00321	0.0161	CbGeAlD
Amoxapine—SLC6A4—female reproductive system—ovarian cancer	0.00304	0.0153	CbGeAlD
Amoxapine—CHRM1—female reproductive system—ovarian cancer	0.00303	0.0152	CbGeAlD
Amoxapine—HTR2B—female reproductive system—ovarian cancer	0.00301	0.0152	CbGeAlD
Amoxapine—SLC6A2—gonad—ovarian cancer	0.003	0.0151	CbGeAlD
Amoxapine—HTR7—gonad—ovarian cancer	0.00289	0.0145	CbGeAlD
Amoxapine—HTR2B—vagina—ovarian cancer	0.00273	0.0137	CbGeAlD
Amoxapine—SLC6A3—testis—ovarian cancer	0.00268	0.0135	CbGeAlD
Amoxapine—SLC6A2—female reproductive system—ovarian cancer	0.00268	0.0135	CbGeAlD
Amoxapine—HTR2A—embryo—ovarian cancer	0.00266	0.0134	CbGeAlD
Amoxapine—HRH1—epithelium—ovarian cancer	0.00259	0.013	CbGeAlD
Amoxapine—HTR7—female reproductive system—ovarian cancer	0.00258	0.013	CbGeAlD
Amoxapine—HRH1—uterine cervix—ovarian cancer	0.00257	0.0129	CbGeAlD
Amoxapine—ADRA2A—uterine cervix—ovarian cancer	0.00253	0.0127	CbGeAlD
Amoxapine—HRH1—decidua—ovarian cancer	0.00245	0.0123	CbGeAlD
Amoxapine—ADRA2A—decidua—ovarian cancer	0.00241	0.0121	CbGeAlD
Amoxapine—HRH1—endometrium—ovarian cancer	0.00233	0.0117	CbGeAlD
Amoxapine—ADRA2A—endometrium—ovarian cancer	0.00229	0.0115	CbGeAlD
Amoxapine—HTR2A—epithelium—ovarian cancer	0.00217	0.0109	CbGeAlD
Amoxapine—SLC6A2—testis—ovarian cancer	0.00216	0.0109	CbGeAlD
Amoxapine—ADRA2A—gonad—ovarian cancer	0.00212	0.0107	CbGeAlD
Amoxapine—ADRA2A—uterus—ovarian cancer	0.00211	0.0106	CbGeAlD
Amoxapine—ORM1—lymph node—ovarian cancer	0.00209	0.0105	CbGeAlD
Amoxapine—HTR7—testis—ovarian cancer	0.00208	0.0105	CbGeAlD
Amoxapine—DRD2—testis—ovarian cancer	0.00197	0.0099	CbGeAlD
Amoxapine—HRH1—female reproductive system—ovarian cancer	0.00193	0.00969	CbGeAlD
Amoxapine—ADRA2A—female reproductive system—ovarian cancer	0.00189	0.00952	CbGeAlD
Amoxapine—HTR2A—gonad—ovarian cancer	0.0018	0.00906	CbGeAlD
Amoxapine—HTR2B—lymph node—ovarian cancer	0.00176	0.00887	CbGeAlD
Amoxapine—HRH1—female gonad—ovarian cancer	0.00175	0.00882	CbGeAlD
Amoxapine—HRH1—vagina—ovarian cancer	0.00174	0.00876	CbGeAlD
Amoxapine—ADRA2A—female gonad—ovarian cancer	0.00172	0.00866	CbGeAlD
Amoxapine—ADRA2A—vagina—ovarian cancer	0.00171	0.00861	CbGeAlD
Amoxapine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.00171	0.00261	CcSEcCtD
Amoxapine—Desloratadine—ABCB1—ovarian cancer	0.0017	0.384	CrCbGaD
Amoxapine—Mental disability—Epirubicin—ovarian cancer	0.00169	0.00259	CcSEcCtD
Amoxapine—Hypotension—Vinorelbine—ovarian cancer	0.00169	0.00259	CcSEcCtD
Amoxapine—Pruritus—Chlorambucil—ovarian cancer	0.00168	0.00258	CcSEcCtD
Amoxapine—Urticaria—Topotecan—ovarian cancer	0.00168	0.00257	CcSEcCtD
Amoxapine—Abdominal pain—Topotecan—ovarian cancer	0.00167	0.00256	CcSEcCtD
Amoxapine—Body temperature increased—Topotecan—ovarian cancer	0.00167	0.00256	CcSEcCtD
Amoxapine—Weight increased—Docetaxel—ovarian cancer	0.00165	0.00253	CcSEcCtD
Amoxapine—Urticaria—Melphalan—ovarian cancer	0.00165	0.00252	CcSEcCtD
Amoxapine—Diarrhoea—Chlorambucil—ovarian cancer	0.00163	0.00249	CcSEcCtD
Amoxapine—Paraesthesia—Vinorelbine—ovarian cancer	0.00163	0.00249	CcSEcCtD
Amoxapine—HTR2A—female reproductive system—ovarian cancer	0.00161	0.00809	CbGeAlD
Amoxapine—Tinnitus—Paclitaxel—ovarian cancer	0.0016	0.00245	CcSEcCtD
Amoxapine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.0016	0.00244	CcSEcCtD
Amoxapine—Myocardial infarction—Docetaxel—ovarian cancer	0.00159	0.00243	CcSEcCtD
Amoxapine—Vascular purpura—Epirubicin—ovarian cancer	0.00158	0.00242	CcSEcCtD
Amoxapine—Jaundice—Docetaxel—ovarian cancer	0.00158	0.00242	CcSEcCtD
Amoxapine—Stomatitis—Docetaxel—ovarian cancer	0.00158	0.00242	CcSEcCtD
Amoxapine—Decreased appetite—Vinorelbine—ovarian cancer	0.00157	0.00241	CcSEcCtD
Amoxapine—Mental disability—Doxorubicin—ovarian cancer	0.00157	0.0024	CcSEcCtD
Amoxapine—SLC6A2—lymph node—ovarian cancer	0.00157	0.00788	CbGeAlD
Amoxapine—Fatigue—Vinorelbine—ovarian cancer	0.00156	0.00239	CcSEcCtD
Amoxapine—HRH1—testis—ovarian cancer	0.00156	0.00782	CbGeAlD
Amoxapine—Constipation—Vinorelbine—ovarian cancer	0.00155	0.00237	CcSEcCtD
Amoxapine—ADRA2A—testis—ovarian cancer	0.00153	0.00768	CbGeAlD
Amoxapine—Asthenia—Topotecan—ovarian cancer	0.00152	0.00232	CcSEcCtD
Amoxapine—Alopecia—Paclitaxel—ovarian cancer	0.00151	0.00232	CcSEcCtD
Amoxapine—Vomiting—Chlorambucil—ovarian cancer	0.00151	0.00231	CcSEcCtD
Amoxapine—Agranulocytosis—Docetaxel—ovarian cancer	0.00151	0.00231	CcSEcCtD
Amoxapine—Increased appetite—Epirubicin—ovarian cancer	0.00151	0.00231	CcSEcCtD
Amoxapine—Pruritus—Topotecan—ovarian cancer	0.0015	0.00229	CcSEcCtD
Amoxapine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00149	0.00228	CcSEcCtD
Amoxapine—Asthenia—Melphalan—ovarian cancer	0.00149	0.00228	CcSEcCtD
Amoxapine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00148	0.00227	CcSEcCtD
Amoxapine—Flatulence—Paclitaxel—ovarian cancer	0.00147	0.00225	CcSEcCtD
Amoxapine—Purpura—Epirubicin—ovarian cancer	0.00147	0.00225	CcSEcCtD
Amoxapine—CYP2D6—female reproductive system—ovarian cancer	0.00147	0.00737	CbGeAlD
Amoxapine—Pruritus—Melphalan—ovarian cancer	0.00147	0.00224	CcSEcCtD
Amoxapine—Vascular purpura—Doxorubicin—ovarian cancer	0.00147	0.00224	CcSEcCtD
Amoxapine—Tension—Paclitaxel—ovarian cancer	0.00146	0.00224	CcSEcCtD
Amoxapine—Dysgeusia—Paclitaxel—ovarian cancer	0.00146	0.00224	CcSEcCtD
Amoxapine—HTR2A—vagina—ovarian cancer	0.00146	0.00732	CbGeAlD
Amoxapine—Hepatitis—Docetaxel—ovarian cancer	0.00145	0.00222	CcSEcCtD
Amoxapine—Nervousness—Paclitaxel—ovarian cancer	0.00145	0.00222	CcSEcCtD
Amoxapine—Diarrhoea—Topotecan—ovarian cancer	0.00145	0.00222	CcSEcCtD
Amoxapine—Hypoaesthesia—Docetaxel—ovarian cancer	0.00145	0.00221	CcSEcCtD
Amoxapine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00145	0.00221	CcSEcCtD
Amoxapine—Urticaria—Vinorelbine—ovarian cancer	0.00144	0.0022	CcSEcCtD
Amoxapine—Abdominal pain—Vinorelbine—ovarian cancer	0.00143	0.00219	CcSEcCtD
Amoxapine—Body temperature increased—Vinorelbine—ovarian cancer	0.00143	0.00219	CcSEcCtD
Amoxapine—Diarrhoea—Melphalan—ovarian cancer	0.00142	0.00217	CcSEcCtD
Amoxapine—Nausea—Chlorambucil—ovarian cancer	0.00141	0.00216	CcSEcCtD
Amoxapine—Vision blurred—Paclitaxel—ovarian cancer	0.00141	0.00215	CcSEcCtD
Amoxapine—Dizziness—Topotecan—ovarian cancer	0.0014	0.00214	CcSEcCtD
Amoxapine—Tremor—Paclitaxel—ovarian cancer	0.0014	0.00214	CcSEcCtD
Amoxapine—Increased appetite—Doxorubicin—ovarian cancer	0.0014	0.00214	CcSEcCtD
Amoxapine—Agitation—Paclitaxel—ovarian cancer	0.00137	0.0021	CcSEcCtD
Amoxapine—Purpura—Doxorubicin—ovarian cancer	0.00136	0.00208	CcSEcCtD
Amoxapine—Vomiting—Topotecan—ovarian cancer	0.00135	0.00206	CcSEcCtD
Amoxapine—Syncope—Paclitaxel—ovarian cancer	0.00134	0.00205	CcSEcCtD
Amoxapine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.00134	0.00205	CcSEcCtD
Amoxapine—Leukopenia—Paclitaxel—ovarian cancer	0.00134	0.00204	CcSEcCtD
Amoxapine—Rash—Topotecan—ovarian cancer	0.00133	0.00204	CcSEcCtD
Amoxapine—CYP2D6—female gonad—ovarian cancer	0.00133	0.00671	CbGeAlD
Amoxapine—Dermatitis—Topotecan—ovarian cancer	0.00133	0.00204	CcSEcCtD
Amoxapine—Ataxia—Epirubicin—ovarian cancer	0.00133	0.00204	CcSEcCtD
Amoxapine—Headache—Topotecan—ovarian cancer	0.00133	0.00203	CcSEcCtD
Amoxapine—Palpitations—Paclitaxel—ovarian cancer	0.00132	0.00202	CcSEcCtD
Amoxapine—Vomiting—Melphalan—ovarian cancer	0.00132	0.00202	CcSEcCtD
Amoxapine—Loss of consciousness—Paclitaxel—ovarian cancer	0.00131	0.00201	CcSEcCtD
Amoxapine—Rash—Melphalan—ovarian cancer	0.00131	0.002	CcSEcCtD
Amoxapine—Dermatitis—Melphalan—ovarian cancer	0.00131	0.002	CcSEcCtD
Amoxapine—HTR2A—testis—ovarian cancer	0.0013	0.00653	CbGeAlD
Amoxapine—Asthenia—Vinorelbine—ovarian cancer	0.0013	0.00199	CcSEcCtD
Amoxapine—Convulsion—Paclitaxel—ovarian cancer	0.00129	0.00198	CcSEcCtD
Amoxapine—Hypertension—Paclitaxel—ovarian cancer	0.00129	0.00197	CcSEcCtD
Amoxapine—Alopecia—Docetaxel—ovarian cancer	0.00128	0.00197	CcSEcCtD
Amoxapine—Pruritus—Vinorelbine—ovarian cancer	0.00128	0.00196	CcSEcCtD
Amoxapine—Nausea—Topotecan—ovarian cancer	0.00126	0.00192	CcSEcCtD
Amoxapine—Dry mouth—Paclitaxel—ovarian cancer	0.00124	0.0019	CcSEcCtD
Amoxapine—Diarrhoea—Vinorelbine—ovarian cancer	0.00124	0.0019	CcSEcCtD
Amoxapine—Dysgeusia—Docetaxel—ovarian cancer	0.00124	0.0019	CcSEcCtD
Amoxapine—Ataxia—Doxorubicin—ovarian cancer	0.00123	0.00189	CcSEcCtD
Amoxapine—Nausea—Melphalan—ovarian cancer	0.00123	0.00188	CcSEcCtD
Amoxapine—Confusional state—Paclitaxel—ovarian cancer	0.00123	0.00188	CcSEcCtD
Amoxapine—Oedema—Paclitaxel—ovarian cancer	0.00122	0.00186	CcSEcCtD
Amoxapine—Eosinophilia—Epirubicin—ovarian cancer	0.00121	0.00186	CcSEcCtD
Amoxapine—Pancreatitis—Epirubicin—ovarian cancer	0.0012	0.00184	CcSEcCtD
Amoxapine—Shock—Paclitaxel—ovarian cancer	0.0012	0.00183	CcSEcCtD
Amoxapine—Dizziness—Vinorelbine—ovarian cancer	0.0012	0.00183	CcSEcCtD
Amoxapine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00119	0.00183	CcSEcCtD
Amoxapine—Tachycardia—Paclitaxel—ovarian cancer	0.00119	0.00182	CcSEcCtD
Amoxapine—CYP2D6—testis—ovarian cancer	0.00118	0.00595	CbGeAlD
Amoxapine—Anorexia—Paclitaxel—ovarian cancer	0.00116	0.00178	CcSEcCtD
Amoxapine—Vomiting—Vinorelbine—ovarian cancer	0.00115	0.00176	CcSEcCtD
Amoxapine—Rash—Vinorelbine—ovarian cancer	0.00114	0.00175	CcSEcCtD
Amoxapine—Dermatitis—Vinorelbine—ovarian cancer	0.00114	0.00175	CcSEcCtD
Amoxapine—Hypotension—Paclitaxel—ovarian cancer	0.00114	0.00174	CcSEcCtD
Amoxapine—Headache—Vinorelbine—ovarian cancer	0.00113	0.00174	CcSEcCtD
Amoxapine—Syncope—Docetaxel—ovarian cancer	0.00113	0.00174	CcSEcCtD
Amoxapine—Leukopenia—Docetaxel—ovarian cancer	0.00113	0.00173	CcSEcCtD
Amoxapine—Pollakiuria—Epirubicin—ovarian cancer	0.00113	0.00173	CcSEcCtD
Amoxapine—HRH1—lymph node—ovarian cancer	0.00113	0.00567	CbGeAlD
Amoxapine—Eosinophilia—Doxorubicin—ovarian cancer	0.00112	0.00172	CcSEcCtD
Amoxapine—Palpitations—Docetaxel—ovarian cancer	0.00112	0.00171	CcSEcCtD
Amoxapine—Weight increased—Epirubicin—ovarian cancer	0.00111	0.00171	CcSEcCtD
Amoxapine—Loss of consciousness—Docetaxel—ovarian cancer	0.00111	0.0017	CcSEcCtD
Amoxapine—Pancreatitis—Doxorubicin—ovarian cancer	0.00111	0.0017	CcSEcCtD
Amoxapine—ADRA2A—lymph node—ovarian cancer	0.00111	0.00557	CbGeAlD
Amoxapine—Clozapine—CYP1B1—ovarian cancer	0.00111	0.25	CrCbGaD
Amoxapine—Insomnia—Paclitaxel—ovarian cancer	0.0011	0.00169	CcSEcCtD
Amoxapine—Convulsion—Docetaxel—ovarian cancer	0.0011	0.00168	CcSEcCtD
Amoxapine—Paraesthesia—Paclitaxel—ovarian cancer	0.00109	0.00167	CcSEcCtD
Amoxapine—Hypertension—Docetaxel—ovarian cancer	0.00109	0.00167	CcSEcCtD
Amoxapine—Drowsiness—Epirubicin—ovarian cancer	0.00109	0.00167	CcSEcCtD
Amoxapine—Somnolence—Paclitaxel—ovarian cancer	0.00108	0.00166	CcSEcCtD
Amoxapine—Nausea—Vinorelbine—ovarian cancer	0.00108	0.00165	CcSEcCtD
Amoxapine—Dyspepsia—Paclitaxel—ovarian cancer	0.00107	0.00164	CcSEcCtD
Amoxapine—Stomatitis—Epirubicin—ovarian cancer	0.00106	0.00163	CcSEcCtD
Amoxapine—Jaundice—Epirubicin—ovarian cancer	0.00106	0.00163	CcSEcCtD
Amoxapine—Decreased appetite—Paclitaxel—ovarian cancer	0.00106	0.00162	CcSEcCtD
Amoxapine—Dry mouth—Docetaxel—ovarian cancer	0.00105	0.00161	CcSEcCtD
Amoxapine—Fatigue—Paclitaxel—ovarian cancer	0.00105	0.00161	CcSEcCtD
Amoxapine—Pollakiuria—Doxorubicin—ovarian cancer	0.00105	0.0016	CcSEcCtD
Amoxapine—Constipation—Paclitaxel—ovarian cancer	0.00104	0.00159	CcSEcCtD
Amoxapine—Confusional state—Docetaxel—ovarian cancer	0.00104	0.00159	CcSEcCtD
Amoxapine—Oedema—Docetaxel—ovarian cancer	0.00103	0.00158	CcSEcCtD
Amoxapine—Weight increased—Doxorubicin—ovarian cancer	0.00103	0.00158	CcSEcCtD
Amoxapine—Agranulocytosis—Epirubicin—ovarian cancer	0.00102	0.00156	CcSEcCtD
Amoxapine—Shock—Docetaxel—ovarian cancer	0.00102	0.00155	CcSEcCtD
Amoxapine—Thrombocytopenia—Docetaxel—ovarian cancer	0.00101	0.00155	CcSEcCtD
Amoxapine—Drowsiness—Doxorubicin—ovarian cancer	0.00101	0.00155	CcSEcCtD
Amoxapine—Tachycardia—Docetaxel—ovarian cancer	0.00101	0.00154	CcSEcCtD
Amoxapine—Feeling abnormal—Paclitaxel—ovarian cancer	0.001	0.00154	CcSEcCtD
Amoxapine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000996	0.00152	CcSEcCtD
Amoxapine—Jaundice—Doxorubicin—ovarian cancer	0.000985	0.00151	CcSEcCtD
Amoxapine—Stomatitis—Doxorubicin—ovarian cancer	0.000985	0.00151	CcSEcCtD
Amoxapine—Anorexia—Docetaxel—ovarian cancer	0.000984	0.00151	CcSEcCtD
Amoxapine—Hepatitis—Epirubicin—ovarian cancer	0.00098	0.0015	CcSEcCtD
Amoxapine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000975	0.00149	CcSEcCtD
Amoxapine—Urticaria—Paclitaxel—ovarian cancer	0.000967	0.00148	CcSEcCtD
Amoxapine—Hypotension—Docetaxel—ovarian cancer	0.000965	0.00148	CcSEcCtD
Amoxapine—Abdominal pain—Paclitaxel—ovarian cancer	0.000963	0.00147	CcSEcCtD
Amoxapine—Body temperature increased—Paclitaxel—ovarian cancer	0.000963	0.00147	CcSEcCtD
Amoxapine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000943	0.00144	CcSEcCtD
Amoxapine—Insomnia—Docetaxel—ovarian cancer	0.000934	0.00143	CcSEcCtD
Amoxapine—Paraesthesia—Docetaxel—ovarian cancer	0.000927	0.00142	CcSEcCtD
Amoxapine—Somnolence—Docetaxel—ovarian cancer	0.000918	0.0014	CcSEcCtD
Amoxapine—Tinnitus—Epirubicin—ovarian cancer	0.000914	0.0014	CcSEcCtD
Amoxapine—Dyspepsia—Docetaxel—ovarian cancer	0.000909	0.00139	CcSEcCtD
Amoxapine—Hepatitis—Doxorubicin—ovarian cancer	0.000907	0.00139	CcSEcCtD
Amoxapine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000902	0.00138	CcSEcCtD
Amoxapine—Decreased appetite—Docetaxel—ovarian cancer	0.000897	0.00137	CcSEcCtD
Amoxapine—Fatigue—Docetaxel—ovarian cancer	0.00089	0.00136	CcSEcCtD
Amoxapine—Constipation—Docetaxel—ovarian cancer	0.000883	0.00135	CcSEcCtD
Amoxapine—Asthenia—Paclitaxel—ovarian cancer	0.000874	0.00134	CcSEcCtD
Amoxapine—Alopecia—Epirubicin—ovarian cancer	0.000866	0.00133	CcSEcCtD
Amoxapine—Pruritus—Paclitaxel—ovarian cancer	0.000862	0.00132	CcSEcCtD
Amoxapine—Feeling abnormal—Docetaxel—ovarian cancer	0.000851	0.0013	CcSEcCtD
Amoxapine—Tinnitus—Doxorubicin—ovarian cancer	0.000845	0.00129	CcSEcCtD
Amoxapine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000844	0.00129	CcSEcCtD
Amoxapine—Flatulence—Epirubicin—ovarian cancer	0.000841	0.00129	CcSEcCtD
Amoxapine—Tension—Epirubicin—ovarian cancer	0.000837	0.00128	CcSEcCtD
Amoxapine—Dysgeusia—Epirubicin—ovarian cancer	0.000835	0.00128	CcSEcCtD
Amoxapine—Diarrhoea—Paclitaxel—ovarian cancer	0.000833	0.00128	CcSEcCtD
Amoxapine—Nervousness—Epirubicin—ovarian cancer	0.000829	0.00127	CcSEcCtD
Amoxapine—Body temperature increased—Docetaxel—ovarian cancer	0.000816	0.00125	CcSEcCtD
Amoxapine—Abdominal pain—Docetaxel—ovarian cancer	0.000816	0.00125	CcSEcCtD
Amoxapine—Dizziness—Paclitaxel—ovarian cancer	0.000805	0.00123	CcSEcCtD
Amoxapine—Vision blurred—Epirubicin—ovarian cancer	0.000804	0.00123	CcSEcCtD
Amoxapine—Alopecia—Doxorubicin—ovarian cancer	0.000801	0.00123	CcSEcCtD
Amoxapine—Agitation—Epirubicin—ovarian cancer	0.000784	0.0012	CcSEcCtD
Amoxapine—Flatulence—Doxorubicin—ovarian cancer	0.000778	0.00119	CcSEcCtD
Amoxapine—Tension—Doxorubicin—ovarian cancer	0.000775	0.00119	CcSEcCtD
Amoxapine—Vomiting—Paclitaxel—ovarian cancer	0.000774	0.00119	CcSEcCtD
Amoxapine—Dysgeusia—Doxorubicin—ovarian cancer	0.000773	0.00118	CcSEcCtD
Amoxapine—Rash—Paclitaxel—ovarian cancer	0.000768	0.00118	CcSEcCtD
Amoxapine—Dermatitis—Paclitaxel—ovarian cancer	0.000767	0.00117	CcSEcCtD
Amoxapine—Nervousness—Doxorubicin—ovarian cancer	0.000767	0.00117	CcSEcCtD
Amoxapine—Syncope—Epirubicin—ovarian cancer	0.000765	0.00117	CcSEcCtD
Amoxapine—Leukopenia—Epirubicin—ovarian cancer	0.000764	0.00117	CcSEcCtD
Amoxapine—Headache—Paclitaxel—ovarian cancer	0.000763	0.00117	CcSEcCtD
Amoxapine—Palpitations—Epirubicin—ovarian cancer	0.000754	0.00115	CcSEcCtD
Amoxapine—Loss of consciousness—Epirubicin—ovarian cancer	0.00075	0.00115	CcSEcCtD
Amoxapine—Vision blurred—Doxorubicin—ovarian cancer	0.000744	0.00114	CcSEcCtD
Amoxapine—Asthenia—Docetaxel—ovarian cancer	0.000741	0.00113	CcSEcCtD
Amoxapine—Convulsion—Epirubicin—ovarian cancer	0.000739	0.00113	CcSEcCtD
Amoxapine—Hypertension—Epirubicin—ovarian cancer	0.000737	0.00113	CcSEcCtD
Amoxapine—Pruritus—Docetaxel—ovarian cancer	0.00073	0.00112	CcSEcCtD
Amoxapine—Agitation—Doxorubicin—ovarian cancer	0.000725	0.00111	CcSEcCtD
Amoxapine—Nausea—Paclitaxel—ovarian cancer	0.000723	0.00111	CcSEcCtD
Amoxapine—Dry mouth—Epirubicin—ovarian cancer	0.00071	0.00109	CcSEcCtD
Amoxapine—Syncope—Doxorubicin—ovarian cancer	0.000708	0.00108	CcSEcCtD
Amoxapine—Leukopenia—Doxorubicin—ovarian cancer	0.000707	0.00108	CcSEcCtD
Amoxapine—Diarrhoea—Docetaxel—ovarian cancer	0.000706	0.00108	CcSEcCtD
Amoxapine—Confusional state—Epirubicin—ovarian cancer	0.000702	0.00107	CcSEcCtD
Amoxapine—Palpitations—Doxorubicin—ovarian cancer	0.000698	0.00107	CcSEcCtD
Amoxapine—Oedema—Epirubicin—ovarian cancer	0.000696	0.00107	CcSEcCtD
Amoxapine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000694	0.00106	CcSEcCtD
Amoxapine—Shock—Epirubicin—ovarian cancer	0.000685	0.00105	CcSEcCtD
Amoxapine—Convulsion—Doxorubicin—ovarian cancer	0.000684	0.00105	CcSEcCtD
Amoxapine—Dizziness—Docetaxel—ovarian cancer	0.000683	0.00104	CcSEcCtD
Amoxapine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000682	0.00104	CcSEcCtD
Amoxapine—Hypertension—Doxorubicin—ovarian cancer	0.000681	0.00104	CcSEcCtD
Amoxapine—Tachycardia—Epirubicin—ovarian cancer	0.00068	0.00104	CcSEcCtD
Amoxapine—Anorexia—Epirubicin—ovarian cancer	0.000664	0.00102	CcSEcCtD
Amoxapine—Dry mouth—Doxorubicin—ovarian cancer	0.000657	0.00101	CcSEcCtD
Amoxapine—Vomiting—Docetaxel—ovarian cancer	0.000656	0.001	CcSEcCtD
Amoxapine—Rash—Docetaxel—ovarian cancer	0.000651	0.000996	CcSEcCtD
Amoxapine—Hypotension—Epirubicin—ovarian cancer	0.000651	0.000996	CcSEcCtD
Amoxapine—Dermatitis—Docetaxel—ovarian cancer	0.00065	0.000995	CcSEcCtD
Amoxapine—Confusional state—Doxorubicin—ovarian cancer	0.00065	0.000994	CcSEcCtD
Amoxapine—Headache—Docetaxel—ovarian cancer	0.000647	0.00099	CcSEcCtD
Amoxapine—Oedema—Doxorubicin—ovarian cancer	0.000644	0.000986	CcSEcCtD
Amoxapine—Shock—Doxorubicin—ovarian cancer	0.000634	0.00097	CcSEcCtD
Amoxapine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000631	0.000966	CcSEcCtD
Amoxapine—Insomnia—Epirubicin—ovarian cancer	0.00063	0.000964	CcSEcCtD
Amoxapine—Tachycardia—Doxorubicin—ovarian cancer	0.000629	0.000963	CcSEcCtD
Amoxapine—Paraesthesia—Epirubicin—ovarian cancer	0.000625	0.000957	CcSEcCtD
Amoxapine—Somnolence—Epirubicin—ovarian cancer	0.000619	0.000948	CcSEcCtD
Amoxapine—Anorexia—Doxorubicin—ovarian cancer	0.000614	0.00094	CcSEcCtD
Amoxapine—Nausea—Docetaxel—ovarian cancer	0.000613	0.000939	CcSEcCtD
Amoxapine—Dyspepsia—Epirubicin—ovarian cancer	0.000613	0.000938	CcSEcCtD
Amoxapine—Olanzapine—ABCB1—ovarian cancer	0.000608	0.138	CrCbGaD
Amoxapine—Decreased appetite—Epirubicin—ovarian cancer	0.000605	0.000927	CcSEcCtD
Amoxapine—Hypotension—Doxorubicin—ovarian cancer	0.000602	0.000922	CcSEcCtD
Amoxapine—Fatigue—Epirubicin—ovarian cancer	0.0006	0.000919	CcSEcCtD
Amoxapine—Constipation—Epirubicin—ovarian cancer	0.000595	0.000911	CcSEcCtD
Amoxapine—Insomnia—Doxorubicin—ovarian cancer	0.000583	0.000892	CcSEcCtD
Amoxapine—Paraesthesia—Doxorubicin—ovarian cancer	0.000578	0.000886	CcSEcCtD
Amoxapine—Feeling abnormal—Epirubicin—ovarian cancer	0.000574	0.000878	CcSEcCtD
Amoxapine—Somnolence—Doxorubicin—ovarian cancer	0.000573	0.000877	CcSEcCtD
Amoxapine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000569	0.000872	CcSEcCtD
Amoxapine—Dyspepsia—Doxorubicin—ovarian cancer	0.000567	0.000868	CcSEcCtD
Amoxapine—Decreased appetite—Doxorubicin—ovarian cancer	0.00056	0.000857	CcSEcCtD
Amoxapine—Fatigue—Doxorubicin—ovarian cancer	0.000555	0.00085	CcSEcCtD
Amoxapine—Urticaria—Epirubicin—ovarian cancer	0.000553	0.000847	CcSEcCtD
Amoxapine—Constipation—Doxorubicin—ovarian cancer	0.000551	0.000843	CcSEcCtD
Amoxapine—Body temperature increased—Epirubicin—ovarian cancer	0.00055	0.000843	CcSEcCtD
Amoxapine—Abdominal pain—Epirubicin—ovarian cancer	0.00055	0.000843	CcSEcCtD
Amoxapine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000531	0.000813	CcSEcCtD
Amoxapine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000527	0.000806	CcSEcCtD
Amoxapine—Urticaria—Doxorubicin—ovarian cancer	0.000512	0.000783	CcSEcCtD
Amoxapine—Abdominal pain—Doxorubicin—ovarian cancer	0.000509	0.00078	CcSEcCtD
Amoxapine—Body temperature increased—Doxorubicin—ovarian cancer	0.000509	0.00078	CcSEcCtD
Amoxapine—Asthenia—Epirubicin—ovarian cancer	0.0005	0.000765	CcSEcCtD
Amoxapine—Pruritus—Epirubicin—ovarian cancer	0.000493	0.000754	CcSEcCtD
Amoxapine—Diarrhoea—Epirubicin—ovarian cancer	0.000476	0.000729	CcSEcCtD
Amoxapine—Asthenia—Doxorubicin—ovarian cancer	0.000462	0.000708	CcSEcCtD
Amoxapine—Dizziness—Epirubicin—ovarian cancer	0.00046	0.000705	CcSEcCtD
Amoxapine—Pruritus—Doxorubicin—ovarian cancer	0.000456	0.000698	CcSEcCtD
Amoxapine—Vomiting—Epirubicin—ovarian cancer	0.000443	0.000678	CcSEcCtD
Amoxapine—Diarrhoea—Doxorubicin—ovarian cancer	0.000441	0.000675	CcSEcCtD
Amoxapine—Rash—Epirubicin—ovarian cancer	0.000439	0.000672	CcSEcCtD
Amoxapine—Dermatitis—Epirubicin—ovarian cancer	0.000439	0.000671	CcSEcCtD
Amoxapine—Headache—Epirubicin—ovarian cancer	0.000436	0.000668	CcSEcCtD
Amoxapine—Dizziness—Doxorubicin—ovarian cancer	0.000426	0.000652	CcSEcCtD
Amoxapine—Nausea—Epirubicin—ovarian cancer	0.000414	0.000633	CcSEcCtD
Amoxapine—Vomiting—Doxorubicin—ovarian cancer	0.00041	0.000627	CcSEcCtD
Amoxapine—Rash—Doxorubicin—ovarian cancer	0.000406	0.000622	CcSEcCtD
Amoxapine—Dermatitis—Doxorubicin—ovarian cancer	0.000406	0.000621	CcSEcCtD
Amoxapine—Headache—Doxorubicin—ovarian cancer	0.000404	0.000618	CcSEcCtD
Amoxapine—Nausea—Doxorubicin—ovarian cancer	0.000383	0.000586	CcSEcCtD
Amoxapine—Quetiapine—ABCB1—ovarian cancer	0.000369	0.0835	CrCbGaD
Amoxapine—Diazepam—ABCB1—ovarian cancer	0.000321	0.0727	CrCbGaD
Amoxapine—Clozapine—ABCB1—ovarian cancer	0.000317	0.0718	CrCbGaD
Amoxapine—HTR2C—Signaling Pathways—MMP9—ovarian cancer	1.55e-05	0.000108	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PTEN—ovarian cancer	1.55e-05	0.000108	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MTOR—ovarian cancer	1.55e-05	0.000108	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	1.55e-05	0.000108	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	1.54e-05	0.000108	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MTOR—ovarian cancer	1.54e-05	0.000108	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PTEN—ovarian cancer	1.54e-05	0.000107	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MTOR—ovarian cancer	1.54e-05	0.000107	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PIK3CB—ovarian cancer	1.54e-05	0.000107	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MAPK3—ovarian cancer	1.54e-05	0.000107	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	1.54e-05	0.000107	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—KRAS—ovarian cancer	1.54e-05	0.000107	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MAPK3—ovarian cancer	1.52e-05	0.000106	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	1.52e-05	0.000106	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	1.52e-05	0.000106	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CXCL8—ovarian cancer	1.51e-05	0.000105	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	1.51e-05	0.000105	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	1.5e-05	0.000105	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—HRAS—ovarian cancer	1.5e-05	0.000105	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MYC—ovarian cancer	1.5e-05	0.000104	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	1.49e-05	0.000104	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CXCL8—ovarian cancer	1.48e-05	0.000103	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CXCL8—ovarian cancer	1.48e-05	0.000103	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	1.48e-05	0.000103	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	1.48e-05	0.000103	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MYC—ovarian cancer	1.48e-05	0.000103	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	1.48e-05	0.000103	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—HRAS—ovarian cancer	1.47e-05	0.000103	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—PIK3CA—ovarian cancer	1.47e-05	0.000103	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—HRAS—ovarian cancer	1.47e-05	0.000102	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—KRAS—ovarian cancer	1.47e-05	0.000102	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—MAPK1—ovarian cancer	1.46e-05	0.000102	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—EGFR—ovarian cancer	1.46e-05	0.000102	CbGpPWpGaD
Amoxapine—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	1.46e-05	0.000102	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	1.46e-05	0.000102	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PTEN—ovarian cancer	1.46e-05	0.000101	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	1.45e-05	0.000101	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	1.45e-05	0.000101	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	1.45e-05	0.000101	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	1.45e-05	0.000101	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CASP3—ovarian cancer	1.45e-05	0.000101	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	1.44e-05	0.000101	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—IL2—ovarian cancer	1.44e-05	0.000101	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—MAPK1—ovarian cancer	1.44e-05	0.000101	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—EGFR—ovarian cancer	1.44e-05	0.000101	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—IL6—ovarian cancer	1.44e-05	0.0001	CbGpPWpGaD
Amoxapine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	1.44e-05	0.0001	CbGpPWpGaD
Amoxapine—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	1.43e-05	9.99e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	1.43e-05	9.99e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.43e-05	9.98e-05	CbGpPWpGaD
Amoxapine—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	1.43e-05	9.96e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—TP53—ovarian cancer	1.43e-05	9.95e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	1.43e-05	9.95e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—TP53—ovarian cancer	1.43e-05	9.94e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	1.42e-05	9.92e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	1.42e-05	9.91e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—IL2—ovarian cancer	1.42e-05	9.91e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CASP3—ovarian cancer	1.42e-05	9.9e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—IL2—ovarian cancer	1.42e-05	9.89e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CASP3—ovarian cancer	1.42e-05	9.87e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	1.41e-05	9.86e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—IL2—ovarian cancer	1.41e-05	9.86e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—IL6—ovarian cancer	1.41e-05	9.84e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	1.41e-05	9.83e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.41e-05	9.82e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	1.41e-05	9.82e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	1.41e-05	9.82e-05	CbGpPWpGaD
Amoxapine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	1.41e-05	9.81e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—IL6—ovarian cancer	1.41e-05	9.81e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	1.4e-05	9.75e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.39e-05	9.72e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	1.39e-05	9.72e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	1.39e-05	9.7e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.39e-05	9.7e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—TP53—ovarian cancer	1.39e-05	9.67e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	1.39e-05	9.66e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	1.38e-05	9.65e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—STAT3—ovarian cancer	1.38e-05	9.65e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.38e-05	9.64e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—KRAS—ovarian cancer	1.38e-05	9.64e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—NRAS—ovarian cancer	1.38e-05	9.63e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CCND1—ovarian cancer	1.38e-05	9.61e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.38e-05	9.6e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.37e-05	9.58e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.37e-05	9.57e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.37e-05	9.54e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.37e-05	9.53e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—HRAS—ovarian cancer	1.36e-05	9.52e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	1.36e-05	9.51e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—TP53—ovarian cancer	1.36e-05	9.51e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.36e-05	9.51e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—HRAS—ovarian cancer	1.36e-05	9.51e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.36e-05	9.48e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	1.36e-05	9.46e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	1.35e-05	9.43e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	1.35e-05	9.39e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.35e-05	9.38e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	1.34e-05	9.37e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	1.34e-05	9.37e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.34e-05	9.36e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MMP9—ovarian cancer	1.34e-05	9.33e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.34e-05	9.32e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.33e-05	9.3e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PTEN—ovarian cancer	1.33e-05	9.27e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—HRAS—ovarian cancer	1.33e-05	9.25e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.33e-05	9.24e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	1.32e-05	9.22e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.32e-05	9.21e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	1.32e-05	9.18e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.32e-05	9.17e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	1.31e-05	9.13e-05	CbGpPWpGaD
Amoxapine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.31e-05	9.11e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—IL6—ovarian cancer	1.31e-05	9.11e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—HRAS—ovarian cancer	1.31e-05	9.1e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—IL6—ovarian cancer	1.3e-05	9.1e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.3e-05	9.1e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—TP53—ovarian cancer	1.3e-05	9.08e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.3e-05	9.08e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	1.3e-05	9.05e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	1.29e-05	9.03e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	1.29e-05	9.01e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	1.29e-05	8.97e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MYC—ovarian cancer	1.29e-05	8.97e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.28e-05	8.92e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	1.28e-05	8.91e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	1.27e-05	8.85e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—IL6—ovarian cancer	1.27e-05	8.85e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.26e-05	8.79e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.26e-05	8.78e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	1.26e-05	8.77e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—EGFR—ovarian cancer	1.26e-05	8.77e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.25e-05	8.74e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.25e-05	8.73e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.25e-05	8.73e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—IL6—ovarian cancer	1.25e-05	8.71e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.25e-05	8.7e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—HRAS—ovarian cancer	1.25e-05	8.69e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—TP53—ovarian cancer	1.23e-05	8.56e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.23e-05	8.56e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.22e-05	8.53e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.22e-05	8.48e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.22e-05	8.47e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.21e-05	8.45e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—TP53—ovarian cancer	1.21e-05	8.45e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.21e-05	8.42e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.21e-05	8.4e-05	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.21e-05	8.4e-05	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—AKT1—ovarian cancer	1.2e-05	8.39e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	1.2e-05	8.38e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.2e-05	8.34e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.19e-05	8.32e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.19e-05	8.32e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—IL6—ovarian cancer	1.19e-05	8.31e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.19e-05	8.3e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—STAT3—ovarian cancer	1.19e-05	8.29e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.19e-05	8.29e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.19e-05	8.27e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—NRAS—ovarian cancer	1.19e-05	8.27e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	1.18e-05	8.25e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.18e-05	8.24e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.17e-05	8.19e-05	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—AKT1—ovarian cancer	1.17e-05	8.16e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	1.17e-05	8.16e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	1.17e-05	8.14e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.16e-05	8.1e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—HRAS—ovarian cancer	1.16e-05	8.08e-05	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—AKT1—ovarian cancer	1.15e-05	8.03e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.14e-05	7.97e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.14e-05	7.95e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	1.14e-05	7.92e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MYC—ovarian cancer	1.13e-05	7.87e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—IL6—ovarian cancer	1.12e-05	7.84e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.12e-05	7.8e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.11e-05	7.75e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—IL6—ovarian cancer	1.11e-05	7.74e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MYC—ovarian cancer	1.11e-05	7.73e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MYC—ovarian cancer	1.11e-05	7.71e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.1e-05	7.7e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.1e-05	7.7e-05	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—AKT1—ovarian cancer	1.1e-05	7.67e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.1e-05	7.66e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.1e-05	7.65e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.09e-05	7.61e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.09e-05	7.59e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.09e-05	7.59e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.09e-05	7.58e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.09e-05	7.58e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.09e-05	7.57e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.09e-05	7.57e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.08e-05	7.56e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.08e-05	7.56e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	1.08e-05	7.54e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—EGFR—ovarian cancer	1.08e-05	7.54e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1.06e-05	7.42e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1.06e-05	7.42e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.06e-05	7.37e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.05e-05	7.33e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—KRAS—ovarian cancer	1.04e-05	7.28e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.04e-05	7.25e-05	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—AKT1—ovarian cancer	1.04e-05	7.23e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.03e-05	7.16e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.03e-05	7.16e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—KRAS—ovarian cancer	1.02e-05	7.14e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—AKT1—ovarian cancer	1.02e-05	7.14e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—KRAS—ovarian cancer	1.02e-05	7.12e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.01e-05	7.05e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.01e-05	7.04e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	1.01e-05	7.01e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.01e-05	7.01e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	9.89e-06	6.9e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	9.89e-06	6.89e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—IL6—ovarian cancer	9.67e-06	6.74e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—IL6—ovarian cancer	9.62e-06	6.71e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	9.59e-06	6.68e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PTEN—ovarian cancer	9.48e-06	6.61e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	9.43e-06	6.58e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	9.41e-06	6.56e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	9.38e-06	6.54e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	9.34e-06	6.51e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—TP53—ovarian cancer	9.28e-06	6.47e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	9.24e-06	6.44e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—TP53—ovarian cancer	9.13e-06	6.36e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—TP53—ovarian cancer	9.11e-06	6.35e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—TP53—ovarian cancer	9.08e-06	6.33e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	8.94e-06	6.23e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—AKT1—ovarian cancer	8.92e-06	6.22e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	8.88e-06	6.19e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—HRAS—ovarian cancer	8.87e-06	6.18e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	8.73e-06	6.09e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—HRAS—ovarian cancer	8.71e-06	6.07e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—HRAS—ovarian cancer	8.68e-06	6.05e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	8.58e-06	5.98e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	8.55e-06	5.96e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—IL6—ovarian cancer	8.49e-06	5.92e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—AKT1—ovarian cancer	8.39e-06	5.85e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—IL6—ovarian cancer	8.35e-06	5.82e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—IL6—ovarian cancer	8.34e-06	5.81e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—IL6—ovarian cancer	8.31e-06	5.79e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	8.3e-06	5.79e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	8.18e-06	5.7e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	7.94e-06	5.54e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—AKT1—ovarian cancer	7.83e-06	5.46e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	7.71e-06	5.37e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—AKT1—ovarian cancer	7.69e-06	5.36e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—AKT1—ovarian cancer	7.67e-06	5.34e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	7.6e-06	5.3e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	7.55e-06	5.26e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	7.01e-06	4.89e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	6.69e-06	4.66e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—AKT1—ovarian cancer	5.46e-06	3.81e-05	CbGpPWpGaD
